We have discovered that IL-35 can be used to induce the conversion of conventional CD4+ T-cells into induced regulatory T-cells that have potent suppressive capacity in vitro and in vivo. These cells have been designated iTr35 cells by the inventors. This approach can be used to generate regulatory T-cells to treat autoimmune and inflammatory diseases, such as (but not limited to) type 1 diabetes, MS, arthritis, asthma and allergic diseases, IBD, etc.
regulatory T-cells, autoimmune; IL-35, iTr35 cells
Granted Patents or Published Applications
Granted patents or published applications: Publication No. WO 2010/101870
Related Scientific References
Directly related manuscript pending; For background see:
Collison et al., “Regulatory T Cell Suppression Is Potentiated by Target T-Cells in a Cell Contact, IL-35- and IL-10-Dependent Manner”, J. Immun. 182(10): 6121-6128 (May 2009);
Collison L.W. et al.,“The inhibitory cytokine IL-35 contributes to regulatory T cell function”; Nature 450: 566-569 (2007).
We are currently seeking licensing opportunities in all fields for the development of this technology.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.